Tip os
Log ind
ChemoMetec PR2.jpg

Chemometec’s new growth engine could attract buyers

Top picks in English:

Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes.


BY ELIZABETH MØNSTED JOHANSEN
Offentliggjort 15.03.17 kl. 15:39

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Lundbeck Foundation company goes public

COLOURBOX574526.jpg Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Goodbye to Novo A/S

Top picks in English:

In order to avoid confusion, Novo A/S, the holding company of Novo Nordisk and Novozymes and one of Denmark’s major life science investors, has decided to change its name.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

FDA panel sees cardiovascular benefits from Novo's Victoza

Top picks in English:

With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.

Zealand sees big potential for SBS drug

Top picks in English:

Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.

Forsiden lige nu

Genmab-bosser gafler trecifret milliongevinst på optioner

Jan van de Winkel4.jpg Medicinal & Biotek:

De to øverste chefer i Genmab har udnyttet en ordentlig luns optioner, der betyder, at de to hiver en gevinst hjem på et trecifret millionbeløb.

Globalt hackerangreb rammer Merck

Medicinal & Biotek:

En af ofrene for det globale hackerangreb, der har sat en stribe selskaber ud af kurs, er den amerikanske medicinalgigant Merck.

Medicoselskab bag næsefilter har fortsat underskud

Medico & Rehab:

Det danske medicoselskab Rhinix bokser stadig med underskud og negativ egenkapital. Selskabet, der har penge til året ud, er på partnerjagt.

Investeringsbank: Bavarian-vaccine kan blive en milliardsællert

Medicinal & Biotek:

Der er blockbusterpotentiale i Bavarians vaccine mod RSV, mener investeringsbanken Jefferies.

EU starter kulegravning af medicinalpriser

Medicinal & Biotek:

Farmaverden bevæger sig ind i hidtil ukendt territorium i Europa med en ny, stor antitrust-kulegravning af prissætningen af lægemidler.

Takeda og partner fremlægger ”uimponerende” kræftdata

Medicinal & Biotek:

Markedet er ikke ligefrem overvældet af kliniske data på kræftmidlet Adcetris, som blev fremlagt af japanske Takeda og dets amerikanske partner Seattle Genetics i starten af denne uge.

ANNONCE
ANNONCE


ANNONCE